• SIRION Biotech GmbH
  • Am Klopferspitz 19
  • 82152 Planegg / Martinsried
  • Germany
  • Phone: +49 89 700 961 999
  • moc.hcetoib-noiris@ofni

Dr. Christian Thirion

What is your motivation?

Following an inspiring stay at the Gene Center Munich and a short postdoc at the University of Ulm, I returned to Munich to head a research group focusing on preclinical research in neuromuscular disorders. There I started applying viral vectors for therapeutic purposes. Their inherent potential to provide a curative treatment for diseases like duchenne muscular dystrophy is inspiring. With SIRION Biotech we began to develop viral vector technologies for clinical uses. Today the scope of SIRION’s activities includes viral vector-based vaccines, and the generation of vectors for gene and cell therapies. SIRION Biotech’s flagship technology LentiBOOST® improves manufacturing for CAR-T and hematopoietic stem cell-based therapeutics and enabled the approval of a stem cell product to treat anemias. In the future SIRION will focus on the development of next generation gene delivery vectors for more efficient and affordable treatments.

About your company

SIRION Biotech was founded in 2005 with the goal of creating a new generation of viral vector technologies for gene and cell therapy, and vaccine development. SIRION Biotech develops novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses. Products and technologies from SIRION Biotech are currently being applied in more than 18 clinical trials from early stage clinical phase 1/2 through late stage market approval. SIRION Biotech is headquartered in Munich and has offices and labs in Heidelberg, Paris and Boston. For additional information, please visit

“The IZB is set up for advanced life science research and thus ideal for SIRION. There we collaborate with other start-up companies and access valuable resources.”

Dr. Christian Thirion

Dieter Lingelbach